How was testing for common sexually transmitted infections (STIs) affected by the COVID-19 pandemic?

**Background**
During the COVID-19 pandemic, STI services were initially limited and the CDC recommended testing be prioritized for symptomatic and high-risk individuals. Although these measures may negatively affect case finding, as many STIs are asymptomatic, their impact on routine STI testing is not well defined.

**Methods and Results**
Comparison of average STI test volumes between pandemic (March 1-June 27) and baseline (preceding 60 weeks) periods in people ages 14-49.

These findings suggest a shift toward syndromic STI testing during the COVID-19 pandemic, resulting in missed asymptomatic cases.

For more information about Quest Diagnostics publications, please visit the Clinical Education Center at [Education.QuestDiagnostics.com/Publications](http://Education.QuestDiagnostics.com/Publications).
COVID-19 Pandemic Impact on STI Testing

Article Title: Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the US

Casey N Pinto,¹ Justin K Niles,² Harvey W Kaufman,² Elizabeth M Marlowe,² Damian Alagia,² Guangqing Chi,³ Barbara Van Der Pol⁴
¹Department of Public Health Sciences, PennState College of Medicine, The Pennsylvania State University, Hershey, PA; ²Quest Diagnostics, Secaucus, NJ; ³Department of Agricultural Economics, Sociology, and Education, PennState College of Agriculture Sciences, The Pennsylvania State University, University Park, PA; ⁴Division of Infectious Diseases, School of Medicine, The University of Alabama Birmingham, Birmingham, AL

Citation: Am J Prev Med. Published online May 19, 2021. doi:10.1016/j.amepre.2021.03.009

Background

- The Centers for Disease Control and Prevention (CDC) recommended that, during the COVID-19 pandemic, routine sexual health screening should be deferred; it also recommended that healthcare services be prioritized for patients who were symptomatic for sexually transmitted infections (STIs) over those who were asymptomatic.¹
- Understanding trends in STI testing and positive results during the pandemic may help estimate the number of cases that have been missed.
- **Objective:** To evaluate changes in STI testing during the COVID-19 pandemic, investigators measured changes in test volume and positivity for chlamydia and gonorrhea, the 2 most commonly reported notifiable diseases in the United States.

Methods

- This study retrospectively assessed test volumes and results for chlamydia and gonorrhea at a national clinical reference laboratory. Only patients ages 14 through 49 years (the group accounting for >90% of US STI cases) were included.
- Weekly testing volume during the COVID-19 pandemic (March 1-June 27, 2020) and a baseline period (preceding 60 weeks) was observed.
- The number of positive specimens potentially missed during the pandemic was estimated based on anticipated volume and positivity rates extrapolated from baseline.

Results

- The analysis included >9.3 million test results for chlamydia and >9.3 million test results for gonorrhea; most (92.9%) of these results were from simultaneous testing for both STIs.
- Weekly testing volume during the pandemic declined rapidly and reached a low point in the first week of April (59% decline from baseline for women, 63% for men).
- Declines in test volumes correlated with increased positivity rates for chlamydia ($R^2=0.96$) and gonorrhea ($R^2=0.85$).
- The declines in test volumes suggest that 27,659 (26.4%) cases of chlamydia and 5,577 (16.5%) cases of gonorrhea were missed in March through June of 2020.

Conclusions

- The decrease in testing volumes combined with increased positivity suggests that a higher proportion of patients were tested because of symptoms (rather than for screening) during the first months of the pandemic.
- The long-term implications of missed screening opportunities warrant further studies and planning for future healthcare needs.

Reference